GlaxoSmithKline (GSK) was downgraded to a Hold Rating at Jefferies
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Hosted on MSN1d
GSK lowered to hold by Jefferies, valuation disconnect cited
Jefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
GSK Vaccines’ shingles ad campaign warns about the year-round threat
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
FierceBiotech1d
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
GSK’s Trelegy TV ad depicts the reality of living with COPD
GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...
TipRanks on MSN1d
GSK downgraded to Hold from Buy at Jefferies
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
BioSpace2d
GSK Quits Trade Group BIO as Industry Faces Uncertain Political Future
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
GSK price target lowered to 1,450 GBp from 1,550 GBp at Barclays
Barclays lowered the firm’s price target on GSK (GSK) to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.